BridgeBio Pharma Inc.
BridgeBio Announces Preliminary Financials and Business Updates for 2025
Summary
BridgeBio Pharma, Inc. issued preliminary financial information and presented business updates at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company reported an estimated $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025. Additionally, BridgeBio estimated $146.0 million in net product revenue for Q4 2025 and $362.4 million for the full year. The company also discussed the rapid commercial success of Attruby (acoramidis) for ATTR-CM, a new TTR amyloid depleter antibody program, and the progress of several clinical trials. These updates suggest continued growth and a strong financial position to support future launches.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement